- Home
- AZN vs NVO Comparison
AZN vs NVO Comparison
Compare AZN & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZN | NVO |
|---|---|---|
| Founded | 1992 | 1923 |
| Country | United Kingdom | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.3B | 243.4B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | AZN | NVO |
|---|---|---|
| Price | $89.98 | $48.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | N/A | ★ $54.25 |
| AVG Volume (30 Days) | 5.5M | ★ 21.7M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | 1.70% | ★ 2.56% |
| EPS Growth | ★ 45.02 | 10.06 |
| EPS | ★ 6.02 | 3.67 |
| Revenue | ★ $58,127,000,000.00 | $49,580,393,058.00 |
| Revenue This Year | $11.33 | $9.21 |
| Revenue Next Year | $6.08 | $5.64 |
| P/E Ratio | $14.97 | ★ $13.09 |
| Revenue Growth | 13.52 | ★ 16.64 |
| 52 Week Low | $61.24 | $43.08 |
| 52 Week High | $94.02 | $112.52 |
Technical Indicators
Market Signals| Indicator | AZN | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 45.55 |
| Support Level | $90.14 | $47.30 |
| Resistance Level | $91.28 | $49.71 |
| Average True Range (ATR) | 1.34 | 1.23 |
| MACD | -0.22 | 0.31 |
| Stochastic Oscillator | 29.73 | 74.49 |
Price Performance
Historical ComparisonAbout AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.